drug

lasmiditan

Marketedupdated 2mo ago

by Eli Lilly and Co

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 17, 2028

~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (11)

Jul 6, 2040formulationUS 12071423
Jul 6, 2040formulationUS 12071423
Dec 5, 2037compositionUS 11053214
Dec 5, 2037compositionUS 11053214
Dec 5, 2037compositionUS 11053214
Jul 7, 2030method-of-use (U-2718)US 122572464.0y
Jul 7, 2030method-of-use (U-2718)US 122572464.0y
Jul 7, 2030method-of-use (U-2718)US 122572464.0y
Feb 17, 2028compositionUS 74230501.6y
Feb 17, 2028compositionUS 74230501.6y
Feb 17, 2028compositionUS 74230501.6y

Data sources

ClinicalTrials.gov

last refreshed 32m ago

Found something off?

Trials studying lasmiditan

phase3A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraineterminatedn=566
phase3A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraineterminatedn=851
phase1A Study of Lasmiditan in Healthy Volunteerscompletedn=97